Comparative Pharmacology
Head-to-head clinical analysis: MANDOL versus TAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANDOL versus TAZIDIME.
MANDOL vs TAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1-2 g IV or IM every 4-8 hours; maximum 12 g/day.
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
None Documented
None Documented
Terminal elimination half-life is 1.2-1.8 hours in adults with normal renal function; prolonged to 4-8 hours in moderate renal impairment (CrCl 30-50 mL/min) and >12 hours in severe impairment (CrCl <30 mL/min).
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCefamandole + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefamandole."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateCefamandole + Picosulfuric acid
1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD).
Renal: 65-85% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~15-20% as active drug and metabolites; minor hepatic metabolism.
Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefamandole."